神经保护剂2-亚氨基生物素在大血管闭塞性缺血性卒中血管内取栓患者中的安全性、耐受性和药代动力学
这项单中心、随机、安慰剂对照2a期研究纳入40例大血管闭塞性缺血性卒中取栓患者,每治疗组20例。2-亚氨基生物素(2-IB)安全且耐受良好,药代动力学参数可较好预测;2-IB组严重不良事件6例(30%),安慰剂组11例(55%),死亡率2-IB组15%(3/20)vs 安慰剂组40%(8/20)。疗效需进一步2b/3期临床试验研究。
要点
- 2-IB在大血管闭塞性缺血性卒中取栓患者中安全且耐受良好。
- 2-IB组严重不良事件6例(30%)vs 安慰剂组11例(55%)。
- 2-IB组死亡率15%(3/20)vs 安慰剂组40%(8/20)。
核心结论
- 在大血管闭塞性缺血性卒中接受血管内取栓的患者中,2-IB安全且耐受良好;药代动力学参数可较好预测;2-IB的疗效需进一步2b/3期临床试验研究。
研究设计与样本
- 单中心、随机、安慰剂对照2a期研究,改良意向治疗人群40例,每治疗组20例;2-IB或安慰剂持续输注24小时。
主要发现
- 治疗期间生命体征参数两组无差异;共发生17例严重不良事件,2-IB组6例(30%)vs 安慰剂组11例(55%)。
- 7天时NIHSS评分中位数2-IB组3(IQR 1-11)vs 安慰剂组3(IQR 0-16)。
- 24至48小时梗死体积中位数2-IB组12.5(IQR 8.4-60.5)mL vs 安慰剂组13.7(IQR 4.0-94.5)mL。
- 3个月mRS中位数2-IB组3(IQR 1-3)vs 安慰剂组3(IQR 2-6)。
- 死亡率2-IB组15%(3/20)vs 安慰剂组40%(8/20)。
关键数值与推荐
- 主要结局为治疗后的前28小时生命体征参数和药代动力学参数,以及至7天的严重不良事件所测量的安全性和耐受性。
- 2-IB暴露中位数(AUCavg_4 h)为320(IQR 243-395)ng h/mL。
- 中位年龄76(IQR 66-82)岁,女性占40%。
临床怎么用
- 2-IB在此类取栓患者中安全且耐受良好,药代动力学参数可较好预测,疗效需进一步2b/3期临床试验研究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 2-Iminobiotin (2-IB) is a biotin analog with neuroprotective properties. It selectively inhibits neuronal and inducible nitric oxide synthase. The primary objective of this study was to assess the safety, tolerability, and pharmacokinetics of 2-IB in patients with ischemic stroke due to large-vessel occlusion treated with endovascular thrombectomy. The secondary objective was to investigate preliminary efficacy. METHODS: In this single-center, randomized, placebo-controlled phase 2a study, patients received continuous infusion of 2-IB or placebo for 24 hours. The primary outcome was safety and tolerability measured by vital parameters and pharmacokinetic parameters in the first 28 hours after treatment and serious adverse events up until 7 days. Secondary and additional outcomes included National Institutes of Health Stroke Scale score and infarct volume at 24 to 48 hours, mortality at 90 days, and (baseline-prognosis adjusted) modified Rankin Scale score at 90 days. RESULTS: In the modified intention-to-treat population, 40 patients were randomized, 20 per treatment group. Median age was 76 (interquartile range [IQR], 66-82) years and 40% were female. Baseline characteristics were similar between groups. Vital parameters during treatment did not differ between groups. In total, 17 serious adverse events occurred, 6 (30%) in 2-IB and 11 (55%) in placebo. Median 2-IB exposure (AUCavg_4 h) was 320 (IQR, 243-395) ng h/mL. Median National Institutes of Health Stroke Scale score at 7 days was 3 (IQR, 1-11) in 2-IB and 3 (IQR, 0-16) in placebo. Median infarct volume at 24 to 48 hours was 12.5 (IQR, 8.4-60.5) mL versus 13.7 (IQR, 4.0-94.5) mL. Median modified Rankin Scale at 3 months was 3 (IQR, 1-3) in the 2-IB group versus 3 (2-6) in placebo-treated patients. Mortality was 15% (3/20) in 2-IB versus 40% (8/20) in placebo. CONCLUSIONS: In patients with ischemic stroke with large-vessel occlusion treated with endovascular thrombectomy, 2-IB is safe and well tolerated. Pharmacokinetic parameters could be predicted well. The efficacy of 2-IB needs to be investigated further in a phase 2b/3 clinical trial. REGISTRATION: URL: www.onderzoekmetmensen.nl; Unique identifier: NL-OMON51194.
引用
- Vos EM, Peeters-Scholte CMPCD, Boiten J, et al. Safety, Tolerability, and Pharmacokinetics of the Neuroprotectant 2-Iminobiotin in Patients With Large-Vessel Occlusion Ischemic Stroke Treated With Endovascular Thrombectomy. Stroke. 2025. PMID: 40270284. doi:10.1161/STROKEAHA.125.050560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。